Title : Isoorientin improves scopolamine-induced cognitive impairments by restoring the cholinergic system, antioxidant defense, and p-CREB\/BDNF signaling in the hippocampus and frontal cortex - Ko_2019_Arch.Pharm.Res_42_722 |
Author(s) : Ko YH , Kwon SH , Lee SY , Jang CG |
Ref : Arch Pharm Res , 42 :722 , 2019 |
Abstract :
Isoorientin (ISO) is considered one of the most important flavonoids with various pharmacological effects such as antioxidant, anti-inflammatory, and anti-cancer activities. Despite these beneficial activities, the effects of ISO on learning and memory have not been investigated so far. The current study evaluated the memory-enhancing effects of ISO in a scopolamine-treated mouse model by using the Y-maze and passive avoidance tests. The results showed that ISO (5 and 10 mg/kg, p.o.) treatment significantly improved the cognitive impairments caused by scopolamine. Additionally, ISO significantly decreased scopolamine-induced acetylcholinesterase and thiobarbituric acid reactive substance activities in both the hippocampus and frontal cortex of mice. In addition, ISO significantly increased the levels of total superoxide dismutase induced by scopolamine in the hippocampus and frontal cortex. Moreover, Western blot results indicated that ISO reversed the decreases in expression of phosphorylated cAMP response element binding (CREB) and brain-derived neurotrophic factor (BDNF) in the hippocampus and frontal cortex of scopolamine-treated mice. Thus, our results provide initial evidence that ISO ameliorates scopolamine-induced memory and cognitive impairments partly by restoring the cholinergic system, antioxidant defense, and p-CREB/BDNF signaling pathway, thereby exhibiting memory-enhancing activities. |
PubMedSearch : Ko_2019_Arch.Pharm.Res_42_722 |
PubMedID: 31350730 |
Ko YH, Kwon SH, Lee SY, Jang CG (2019)
Isoorientin improves scopolamine-induced cognitive impairments by restoring the cholinergic system, antioxidant defense, and p-CREB\/BDNF signaling in the hippocampus and frontal cortex
Arch Pharm Res
42 :722
Ko YH, Kwon SH, Lee SY, Jang CG (2019)
Arch Pharm Res
42 :722